ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

CVKD Cadrenal Therapeutics Inc

0.4083
-0.0117 (-2.79%)
最終更新日: 03:05:03
15分遅延
名称 銘柄コード 市場 種別
Cadrenal Therapeutics Inc CVKD NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.0117 -2.79% 0.4083 03:05:03
始値 安値 高値 終値 前日終値
0.403 0.40 0.42 0.42
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/0922:00PRNUSCadrenal Therapeutics Provides First Quarter 2024 Corporate..
2024/5/0919:23EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/4/1205:30PRNUSCadrenal Therapeutics to Participate in Noble Capital..
2024/4/0922:00PRNUSCadrenal Therapeutics Receives FDA Orphan Drug Designation..
2024/3/1122:15EDGAR2Form 8-K - Current report
2024/3/1122:00PRNUSCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate..
2024/3/0607:24EDGAR2Form 8-K - Current report
2024/2/2623:00PRNUSCadrenal Therapeutics to Participate at Technology and Heart..
2024/2/1522:00EDGAR2Form 8-K/A - Current report: [Amend]
2024/2/1306:49EDGAR2Form 8-K - Current report
2024/2/0823:00PRNUSCadrenal Therapeutics Appoints Jeff Cole as Chief Operating..
2024/1/3123:00PRNUSCadrenal Therapeutics Highlights Publication of..
2024/1/2423:00PRNUSCadrenal Therapeutics to Participate in a Fireside Chat at..
2024/1/0423:00PRNUSCadrenal Therapeutics to Present at the Biotech Showcase on..
2023/12/1923:00PRNUSNoble Capital Markets Initiates Coverage on Cadrenal..
2023/12/1223:00PRNUSCadrenal Therapeutics Engages The Sage Group to Advance..
2023/12/0106:15PRNUSCadrenal Therapeutics to Present at the NobleCon 19..
2023/11/0923:15EDGAR2Form 8-K - Current report
2023/11/0923:00PRNUSCadrenal Therapeutics Provides Third Quarter 2023 Corporate..
2023/11/0922:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/10/2406:04EDGAR2Form 8-K - Current report
2023/10/1005:15PRNUSCadrenal Therapeutics to Participate in the Lytham Partners..
2023/9/0905:10EDGAR2Form 8-K - Current report
2023/9/0521:00PRNUSCadrenal Therapeutics Highlights Additional Need for a New..
2023/9/0105:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/9/0105:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/8/3021:00PRNUSCadrenal Therapeutics Expands Evaluation of Tecarfarin for..
2023/8/2905:58EDGAR2Form ARS - Annual Report to Security Holders
2023/8/2905:55EDGAR2Form DEF 14A - Other definitive proxy statements
2023/8/2905:15PRNUSCadrenal Therapeutics to Participate in the H.C. Wainwright..
2023/8/1819:06EDGAR2Form 8-K - Current report
2023/8/1705:10EDGAR2Form 8-K - Current report
2023/8/1705:05EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/8/1022:16EDGAR2Form 8-K - Current report
2023/8/1022:00PRNUSCadrenal Therapeutics Provides Second Quarter 2023 Corporate..
2023/8/1019:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/8/0122:00PRNUSCadrenal Therapeutics Expands Focus for Tecarfarin to..
2023/8/0119:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2023/7/2422:20EDGAR2Form 8-K - Current report
2023/7/2422:15EDGAR2Form S-1 - General form for registration of securities under..
2023/7/2422:00PRNUSCadrenal Therapeutics Announces Appointment of Robert..
2023/7/1505:52EDGAR2Form 8-K - Current report
2023/7/1504:02PRNUSCadrenal Therapeutics Announces Closing of $7.5 Million..
2023/7/1304:17PRNUSCadrenal Therapeutics Announces $7.5 Million Private..
2023/6/0122:00PRNUSCadrenal Therapeutics to Participate in the 2023 BIO..

最近閲覧した銘柄

Delayed Upgrade Clock